Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)

NCT04303169 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

146

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma

Interventions

BIOLOGICAL: Pembrolizumab
BIOLOGICAL: Vibostolimab
BIOLOGICAL: Gebasaxturev
BIOLOGICAL: MK-4830
BIOLOGICAL: Favezelimab + Pembrolizumab
DRUG: ATRA

Sponsor

Merck Sharp & Dohme LLC